Literature DB >> 6199215

The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses.

H Fujiwara, Y Shimizu, Y Takai, N Wakamiya, S Ueda, S Kato, T Hamaoka.   

Abstract

C3H/He mice were immunized to vaccinia virus by inoculating i.p. viable virus. Their spleen cells (SC) were tested for vaccinia virus-reactive helper T cell activity capable of augmenting (a) anti-trinitrophenyl (TNP) cytotoxic T lymphocyte (CTL) response generated from unprimed C3H/He SC (responding cells) or (b) anti-TNP antibody response generated from TNP-primed C3H/He SC (responding cells) by the stimulation with syngeneic SC infected with vaccinia virus and subsequently modified with TNP (virus-self-TNP). The results demonstrate that cultures of responding cells plus 850 rds X-irradiated vaccinia virus-primed SC failed to enhance anti-TNP CTL or plaque-forming cell (PFC) responses when in vitro stimulation was provided by either virus-self or TNP-self alone. In contrast, these cultures resulted in appreciable augmentation of CTL and PFC responses when stimulated by virus-self-TNP. Such a helper activity provided by vaccinia virus-primed SC was revealed to be T cell mediated and antigen specific. These results are discussed in the context of (a) nature of virus helper antigens, (b) mechanism of help and (c) potential of virus help in augmenting CTL and antibody responses to tumor antigens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199215     DOI: 10.1002/eji.1830140212

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.

Authors:  J Shima; T Yoshioka; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  Evaluation of in vivo and in vitro effectivity of immune defense against a spontaneously arising, nonlymphoid rat tumor. II. T cell response after induction of immunogenicity.

Authors:  M Zöller
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  Immunotherapy of tumor-bearing mice utilizing virus help.

Authors:  Y Shimizu; K Hasumi; K Masubuchi; Y Okudaira
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases.

Authors:  S Arakawa; G Hamami; K Umezu; S Kamidono; J Ishigami; S Arakawa
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

5.  The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.

Authors:  T Yoshioka; M Fukuzawa; Y Takai; N Wakamiya; S Ueda; S Kato; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.

Authors:  T Hamaoka; Y Takai; A Kosugi; Y Mizushima; J Shima; T Kusama; H Fujiwara
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients.

Authors:  P Hersey; A Edwards; G D'Alessandro; M MacDonald
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.

Authors:  A Kosugi; J Shima; H Sano; M Ogata; T Kusama; H Fujiwara; T Hamaoka
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

9.  Plant lectin, ATF1011, on the tumor cell surface augments tumor-specific immunity through activation of T cells specific for the lectin.

Authors:  R Yoshimoto; N Kondoh; M Isawa; J Hamuro
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2.

Authors:  T Nishimura; Y Togashi; M Goto; H Yagi; Y Uchiyama; Y Hashimoto
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.